STAGE IVB OVARIAN CANCER AJCC V8
Clinical trials for STAGE IVB OVARIAN CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVB OVARIAN CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVB OVARIAN CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy drug shows promise for hard-to-treat cancers with genetic flaws
Disease control OngoingThis study tests the drug pembrolizumab in people with advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. About 21 adults with metastatic or recurrent cancer took part. Pembrolizu…
Matched conditions: STAGE IVB OVARIAN CANCER AJCC V8
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early-phase trial tested the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they had surgery. The goal was to see if taking olaparib for two cycles could shrink tumors or stop them from growing. Olaparib works…
Matched conditions: STAGE IVB OVARIAN CANCER AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
Blood test may tame Chemo's nerve damage
Knowledge-focused TerminatedThis study looks at whether doctors can consistently measure the chemotherapy drug paclitaxel in the blood of cancer patients. The goal is to see if adjusting the dose based on these levels could reduce nerve damage, a common and severe side effect. About 22 adults with various s…
Matched conditions: STAGE IVB OVARIAN CANCER AJCC V8
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 01, 2026 18:03 UTC